Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Illegal imports of weight-loss drugs top 5,000 through Aug.: customs agency

Korea's customs agency said Thursday the number of attempted illegal imports of weight-loss medications, such as Wegovy and Mounjaro, surged from a year earlier to exceed 5,000. A total of 5,030 cases involving the illegal import of weight-loss drugs through overseas direct purchases and other illicit channels were detected in the January-August period, far exceeding the 1,189 cases tallied for…

Illegal imports of weight-loss drugs top 5,000 through Aug.: customs agency

Korea's customs agency reported a sharp increase in illegal imports of weight-loss drugs, surpassing 5,000 cases from January to August. The agency detected 5,030 instances of unauthorized imports of medications like Wegovy and Mounjaro, compared to just 1,189 cases throughout all of the previous year. Customs officials are collaborating with the Ministry of Food and Drug Safety to enhance inspections of imported medications, aiming to safeguard public health from unauthorized products.

Despite prohibitions on bringing Wegovy and Mounjaro into the country via travelers' hand luggage, more Koreans have been attempting to purchase the drugs from neighboring nations due to price discrepancies. The customs agency employs X-ray scans and baggage inspections, returning or discarding any products that fail to meet import requirements. Should violations exceed mere compliance failures, additional measures will be enforced.

Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at koreatimes.co.kr →

More in Health & Medicine

Celltrion’s Remsima Takes No. 1 Spot in Japan’s Infliximab Market After 11 Years

Celltrion’s infliximab biosimilar Remsima has become the most prescribed infliximab product in Japan, 11 years after entering a market where biosimilars have traditionally faced limited price-driven…

  • Celltrion's Remsima leads Japan's infliximab market with 48% share since 2015
  • Remsima's success in Japan attributed to physicians' prescribing experience and sales capabilities
  • Celltrion plans to launch subcutaneous Remsima SC in Japan in 2027

More from Thursday 17 September →